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Background: The last year of life is one of the most resource-intensive periods for people with cancer. Very little
population-based research has been conducted on end-of-life cancer care in the Australian health care setting. The
objective of this program is to undertake a series of observational studies examining resource use, costs and quality
of end-of-life care in a cohort of elderly cancer decedents using linked, routinely collected data.
Methods/Design: This study forms part of an ongoing cancer health services research program. The cohorts for
the end-of-life research program comprise Australian Government Department of Veterans’ Affairs decedents with
full health care entitlements, residing in NSW for the last 18 months of life and dying between 2005 and 2009. We
used cancer and death registry data to identify our decedent cohorts and their causes of death. The study population
includes 9,862 decedents with a cancer history and 15,483 decedents without a cancer history. The median age at
death is 86 and 87 years in the cancer and non-cancer cohorts, respectively. We will examine resource use and
associated costs in the last 6 months of life using linked claims data to report on health service use, hospitalizations,
emergency department visits and medicines use. We will use best practice methods to examine the nature and extent
of resource use, costs and quality of care based on previously published indicators. We will also examine factors
associated with these outcomes.
Discussion: This will be the first Australian research program and among the first internationally to combine
routinely collected data from primary care and hospital-based care to examine comprehensively end-of-life care
in the elderly. The research program has high translational value, as there is limited evidence about the nature
and quality of care in the Australian end-of-life setting.
Keywords: End-of-life, Cancer, Palliative care, Resource utilization, Costs, Patterns of careBackground
Cancer care imposes a significant burden on health systems
globally with the year following diagnosis and last year of
life being the most resource-intensive stages of care [1].
Relative to the evidence-base supporting clinical decision-
making at the time of a cancer diagnosis, there is limited
understanding about what constitutes quality end-of-life
care [2-5]. Randomized trials of end-of-life treatments and
services remain rare and likely to remain so for ethical and* Correspondence: sallie.pearson@sydney.edu.au
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unless otherwise stated.practical reasons [6-9]. Therefore, researchers need to
utilize other methods and data to examine this important
area of medical practice. Observational research on end-
of-life care can enhance our understanding of patterns of
care in real-world clinical settings and assist in establish-
ing evidence to inform clinical practice, resource alloca-
tion and planning decisions.
Observational studies using linked health administra-
tive datasets to explore patterns of end-of-life care have
increased in recent years. The use of existing data such
as billing claims, linked with cancer and death registry
data facilitates the creation of decedent cohorts to obtain
a comprehensive picture of treatment patterns [3]. Thesel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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broader in scope than primary data collections that are
time- and cost-intensive and generally undertaken in small
numbers of highly selected patients and settings.
We recently conducted a systematic review of all obser-
vational end-of-life studies using administrative health
datasets published over a 20-year period [10]. We syn-
thesized the outcomes of 78 studies that collectively ex-
amined end-of-life resource use and/or costs in over
3.7 million cancer decedents. Despite this large volume
of published work, some important gaps in knowledge
were evident. First, end-of-life care is a global concern,
yet little research has been generated outside the North
American setting. Second, most of the studies in the re-
view focused on hospital care; few examined the full
spectrum of treatments received at life’s end including
medications, palliative services, physician visits and com-
munity care. Finally, few studies compared resource
utilization or costs in cancer patients to those without
a cancer diagnosis.
We identified five Australian studies in the systematic
review [7-9,11,12] that focused on the use of specialist
palliative care services, hospital admissions or emergency
department presentations in a specific end-of-life period.
All but one study was conducted in the state of Western
Australia, and only one included data derived in the last
decade. While these studies demonstrate the opportunities
to explore patterns of end-of-life care in the Australian
setting, they also highlight the need for more contempor-
ary data as well as examining the full range of health care
provision including medication use and community-based
medical care.
The program of research outlined in this protocol makes
use of linked, routinely collected data to examine resource
use, costs and quality of end-of-life cancer care. We will
also examine the factors associated with these outcomes.
We have brought together population-based datasets
collected across multiple Australian health care jurisdic-
tions to create decedent cohorts with and without a previ-
ous cancer history to explore how end-of-life care varies




Australia has a publicly funded universal health care system
entitling all Australian citizens and permanent residents to
a range of subsidized health services. This includes free
treatment in public hospitals (funded jointly by the
Commonwealth and State/Territory governments) and
subsidized treatment in private hospitals (funded jointly
by the Commonwealth and private health insurance). It
also includes a range of subsidized outpatient services
including consultations with medical and selected healthcare professionals (funded by the Commonwealth’s Medi-
care Benefits Scheme, MBS) and medicines prescribed in
hospitals and the community (funded by the Common-
wealth’s Pharmaceutical Benefits Scheme, PBS; medicines
prescribed to public hospital inpatients are covered pri-
marily by the hospital budget).
Our end-of-life research program has been developed
from a larger cancer health services research program that
commenced in 2011. The program focuses on clients
of the Australian Government Department of Veterans’
Affairs (DVA). The DVA funds the health care of eligible
veterans, war widows and widowers and their dependants.
Eligible persons with Gold Repatriation Health Cards
(Gold Card Holders) are entitled to treatment for all
conditions (i.e. all health services subsidized for Austra-
lian citizens plus additional DVA-approved services and
pharmaceutical items not subsidized for the general popu-
lation). White Card Holders are entitled to treatment
for specific-conditions approved by the DVA (other condi-
tions will be treated and subsidized according to the
general population entitlements). The Orange Repatriation
Pharmaceuticals Benefits Card provides eligible British,
other Commonwealth or allied veterans subsidized access to
approved pharmaceuticals according to clinical need [13].
DVA clients are a major subgroup of the Australian
population. In December 2010, they constituted approxi-
mately 6% of those aged 65 years and older and 27% of
Australians aged at least 85 years [14]. Our research pro-
gram is limited to all DVA clients residing in NSW
(Australia’s largest state by population). DVA clients
residing in NSW account for 34% of the Australian DVA
population and have a similar age and gender profile
to clients residing in other Australian states [14]. Add-
itionally, when compared to Australians of similar
age, DVA clients have very similar rates of health ser-
vice use [15].
Overview of data sources
The data infrastructure comprises DVA data holdings
linked with NSW Ministry of Health data collections. The
DVA datasets contain information on services provided to
DVA clients regardless of the location in which they oc-
curred in Australia; the NSW collections contain only data
on services provided in NSW. Our current data holdings
are summarized in Table 1 and detailed below.
Patient information
DVA client database (2004–2010) Contains data on
clients’ sex, dates of birth and death, level and history of
health care entitlement (Gold, White, Orange) and post-
code of residence history mapped to Statistical and Local
Government Areas (SLAs [16] and LGAs [17]). The
SLAs and LGAs form part of the Australian Standard
Geographical Classification [18], established to enable
Table 1 Current data holdings











Client file Demographic information and level of
entitlement
DVA April 1992–January 2010 - X
Residential aged care Residence in aged care facility DVA July 2005–March 2011 -
Registries
Central Cancer Registry Cancer notifications in NSW NSW MoH January 1994–December 2009 ICD-10 ICD-O-3 X x X
Registry of Births, Deaths
and Marriages (RBDM)
Deaths in NSW NSW MoH January 1994–December 2012 - x x x
Cause of death (part
of RBDM)
Cause of death in NSW (coded by Australian
Bureau of Statistics)
NSW MoH January 1994–December 2007 ICD-9 (94–98) ICD-10-AM
(from 97)
x x x
Health service and prescribed medicines datasets^
Repatriation Pharmaceutical
Benefits Scheme
Pharmaceutical items in the Pharmaceutical
Benefits Scheme (PBS) and extra items paid
for by the DVA, dispensed anywhere in
Australia
DVA July 2004–January 2010 R/PBS items mapped to
ATC codes
x X
DVA health services Medical and allied health services in the
Medicare Benefits Schedule (MBS) and
extra items paid for by the DVA, delivered
anywhere in Australia
DVA July 2004–February 2011 MBS items DVA items x X
Admitted Patients Data
Collection
Inpatient separations from all public and
private hospitals in NSW
NSW MoH July 2000–December 2011 ICD-10-AM x x x X
Emergency Department
Data Collection
Emergency department visits to a subset
of public hospitals in NSW
NSW MoH January 2005–June 2012 ICD-9, ICD-10 SNOMED CT X
*The program has ethical approval for annual data updates until 2015.
^Common years across all datasets are 2005–2009.
X denotes primary data sources; x denotes additional data sources.
ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision.
ICD-O-3 International Classification of Diseases for Oncology, 3rd Edition.
ICD-9 International Statistical Classification of Diseases and Related Health Problems 9th Revision.
ICD-10-AM International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification.
ATC Anatomical Therapeutic Chemical.
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classification of areas according to socioeconomic pro-
file and remoteness. We did not obtain individual-level
data on the service history of the clients in our cohort;
however, almost all male DVA clients are veterans of
the Australian armed forces and almost all female clients
are dependants [14].
DVA residential aged care database (2005–2011) The
database contains data on clients’ admission and discharged
dates in residential aged care, discharged reason and type of
care received.
Registers
NSW Registry of Births, Deaths and Marriages
(RBDM) (1994–2007) Contains date and cause of death
according to the Australian Bureau of Statistics (ABS)
cause of death field (ICD-10-AM codes) [19].
NSW Central Cancer Registry (CCR) (1994–2009)
The CCR records cancer diagnoses reportable by law for
NSW residents. The registry is operated according to the
rules of the International Association of Cancer Registries
[20] and records cancer type (ICD-O-3 and ICD-10-AM
codes), date of diagnosis, degree of spread at the time of
first diagnosis for solid tumours and the date and cause of
death (cancer or non-cancer) [21].
Prescribed medicines and health service datasets
Australian Government datasets
Pharmaceutical Benefits Scheme and Repatriation
Pharmaceutical Benefits Scheme (RPBS) (2004–2010)
DVA clients are entitled to all items listed on the
Pharmaceutical Benefits Schedule (PBS-listed items) plus
additional DVA-approved items (the combined listing
hereafter referred to as the RPBS). DVA clients can also
make ad hoc requests for the DVA to subsidize phar-
maceutical items that are not RPBS-listed. The RPBS
dataset contains information on all DVA-subsidized
medicines including the item number, name and
strength, date of prescription, date of supply, quantity
supplied, number of repeats and benefit paid on all
pharmaceutical items subsidized, in whole or part, by
the DVA and dispensed in the community or in private
hospitals. Patients are required to contribute to the cost
of medicines via a co-payment. As of 1 January 2014,
the co-payment is $AUD36.90 for general beneficia-
ries and $AUD6.00 for entitled DVA clients and con-
cessional card holders (those covered by government
entitlements such as low-income earners and welfare
recipients).
Prior to 2012, the RPBS database only recorded
pharmaceutical items attracting a government subsidy as
the dispensing information for items costing less thanthe co-payment was not sent for reimbursement (as the
individual has already paid the full cost). However, in-
complete ascertainment of pharmaceutical items is not
an issue for DVA clients or concession card holders,
as all prescription medicines cost more than the con-
cessional co-payment. In 2012, the government started
collecting data on medicines under co-payment, so in-
complete ascertainment of prescription medicines will
no longer be an issue for the entire Australian popula-
tion. One limitation of the database is that medicines
prescribed to public hospital inpatients are generally not
captured, as they are covered by the hospital budget.
Further, the database does not capture over-the-counter
medicines or prescription medicines not subsidized by
the DVA.
DVA health services (2004–2011) DVA clients are en-
titled to free or subsidized treatment from health care
professionals including general practitioners, specialists,
dentists and allied health professionals. They are also en-
titled to additional DVA-approved treatments not listed
on the MBS for the general Australian population and
DVA clients can make ad hoc requests for subsidy of non-
listed items. This dataset contains the service item num-
ber, service category, date of service and amount paid for
all in-hospital and out-of-hospital health services subsi-
dized by the DVA, including physician visits, diagnostic
and therapeutic procedures (including surgery), dental
services, allied health services and pathology tests.
While the Australian government sets MBS fees, pa-
tient co-payments are uncapped as health care profes-
sionals can charge any amount they choose for their
services. However, if a health care professional elects to
bill Medicare directly for a service that a patient re-
ceives (referred to as “bulk billing”), there is no patient
co-payment. Under legislation, DVA clients are bulk-
billed at the rates specified in the DVA health services
schedules.
New South Wales Government datasets
NSW Admitted Patients Data Collection (APDC)
(2000–2011) This dataset is a census of all inpatient ep-
isodes from public, private and repatriation hospitals, pri-
vate day procedures centres and public nursing homes
in NSW. The APDC holds data on the dates of admis-
sion and separation, up to 50 diagnoses and procedures
(ICD-10-AM), Australian Refined Diagnostic Related Groups
(AR-DRGs), source of referral and separation mode
(discharge, transfer or death).
Emergency Department Data Collection (EDDC)
(2005–2012) This dataset records all emergency department
visits to 90 public emergency departments across NSW.
It includes the date, reasons and outcome of the visit (e.g.
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emergency departments in NSW. Most of the larger
departments contribute data to the EDDC so the
dataset includes the majority of ED attendances [19].
Moreover, using the APDC, it is possible to identify
ED presentations which resulted in an admission to
hospital.
Data linkage
Data linkage was performed by the Centre for Health
Record Linkage (CHeReL) [22], which maintains a linkage
system for health-related data in NSW and the Australian
Capital Territory in accordance with all ethical, legal,
privacy and confidentiality requirements. The CHeReL
keeps a Master Linkage Key that consists of con-
tiously updated links between most NSW Health
datasets.
The DVA provided the CHeReL with an encrypted
client number and personal information for all clients
residing in NSW. The CHeReL then assigned a project
person number (PPN) to each DVA client. A “Project
Key” containing the PPN and encrypted client number
for each respective database was sent to the various data
custodians, who decrypted the client number and attached
the PPN and requested variables, which were then sent to
the researchers stripped of identifying information such
as name and address. The researchers joined all datasets
using the PPNs.
Ethics
Our cancer health services research program was ap-
proved by the NSW Population and Health Services Re-
search Ethics Committee (approval number 2013/11/494)
and the Department of Veterans’Affairs Human Research
Ethics Committee (E013/015). Our end-of-life research
program will be conducted under the auspices of these
approvals; however, research beyond 2015 will be subject
to continued approvals.
Study population
We derived two cohorts for the purposes of our end-
of-life research program; patients with evidence of a
cancer diagnosis and those without a cancer history
(see Figure 1). Both cohorts were restricted to DVA cli-
ents meeting the following criteria:
 Full health care entitlements for the last 12 months
of life (to ensure complete capture of all health
services and medicines).
 Resident of NSW for the last 18 months of life.
 ≥ 65 years old at death.
 Died between 30 June 2005–31 December 2009
 ≥ 1 service claim (hospital, health care service or
medicine) in the last 12 months of life.Cancer cohort eligibility criteria
We included decedents diagnosed with a notifiable can-
cer (C00–C43, C45–C97, D03, D05, D45, D46.0–D46.4,
D46.7, D46.9, D47.1, D47.3) as recorded in the cancer
registry (NSW CCR: January 1994–December 2008) or
notifiable cancer recorded as any cause of death (RBDM:
January 1994–December 2007).
Non-cancer cohort eligibility criteria
We included decedents meeting the following criteria:
1. No diagnosis of a notifiable cancer (C00–C43,
C45–C97, D03, D05, D45, D46.0–D46.4, D46.7,
D46.9, D47.1, D47.3) as reported in the cancer
registry (NSW CCR: January 1994–December
2008).
2. Cancer not listed as any cause of death (RBDM:
January 1994–December 2007).
We also applied additional criteria in order to account
for the following: 1) death from cancer outside the dates
for which we have cause of death information (i.e. after
December 2007) or 2) receipt of a cancer diagnosis out-
side of NSW, in which case the information would not
be captured in the NSW-based registry.
To account for the abovementioned scenarios and en-
sure our non-cancer decedent cohort did not include cli-
ents with a cancer diagnosis/cause of death, we screened
all eligible non-cancer decedents for receipt of services or
medications indicative of cancer treatment. Specifically,
we developed a hierarchy based on hospital services, can-
cer drugs and other health care services:
1. Hospital Services (APDC): We excluded clients who
received a cancer-related procedure(s) (C00–C43,
C45–C97, D03, D05, D45, D46.0–D46.4, D46.7,
D46.9, D47.1, D47.3) in hospital between July 2000
and December 2009.
2. Prescription drugs (R/PBS): We excluded clients
who received cancer drugs between July 2004 and
December 2009. We reviewed all L-class drugs
(ATC, World Health Organization) to determine if
they were indicative of cancer treatment; a clinical
pharmacologist (NB) confirmed whether drugs
administered individually or in combination with
other L-class drugs reflected cancer treatment.
Decedents who received L-class drugs were
excluded from the non-cancer cohort except for
the following: L01AA01, L01AA02, L01BA01,
L01BB02, L01BC02 (in cream form only),
L01XC02, L02AB02, L02AE03, L03AA02,
L03AX03, L04AA06, L04AA13, L04AB01,
L04AB02, L04AB04, L04AD01, L04AX01 and
L04AX03. Clients who received intravenous
DVA Clients
1. Died between 30 Jun 2005-31 Dec 2009
2. Resided in NSW last 18m of life, full health care 
entitlements last 12m life
3. 65 years old at death  




Notifiable Cancer Diagnosis (CCR or ABS): 
C00-C43, C45-C97, D03, D05, D45, D46.0 –
D46.4, D46.7, D46.9, D47.1, D47.3
No Notifiable Cancer Diagnosis
N=16,611
We excluded clients with the following:
Non-cancer cohort
N=15,483
(C00-C43,  C45-C97, D03, D05, D45, 
D46.0 – D46.4, D46.7, D46.9, D47.1,  
D47.3) 
n=748
(2) PBS: L-class drugs indicative of 
cancer treatment [other than non-
melanoma skin]
n=187
(4) ABS: Non-notifiable cancer listed 
as cause of death (C44, D01-D02, 
D04, D06-D09, D10-D44, D46.5, 
D47.0, D47.2, D47.4-D48.9)
n=53
(3) MBS: health services related to cancer  
treatment [other than non-
melanoma skin]
n=140
(1) APDC: cancer-related hospital episodes  
Figure 1 Cohort inclusion criteria.
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form) were excluded from the cohort.
3. Health care services: We excluded clients who
received medical services likely to indicate cancer
surgery or treatment between July 2004 and
December 2009. We reviewed all DVA health care
services and excluded clients with a record of
chemotherapy, radiation oncology, surgery or amulti-disciplinary cancer care/case conference. A
practicing medical doctor reviewed the records of all
patients in receipt of such services and confirmed
they most likely reflected cancer care.
4. Finally, we excluded clients with a non-notifiable
cancer cause of death as listed in the RBDM (ICD10:
C44, D01–D02, D04, D06–D09, D10–D44, D46.5,
D47.0, D47.2, D47.4–D48.9).
Table 2 Characteristics of cancer and non-cancer cohorts
Cancer cohort Non-cancer cohort
n = 9,862 n = 15,483
n (%) n (%)
Sex
Female 3,116 (31.6) 7,521 (48.9)
Male 6,746 (68.4) 7,962 (51.4)
Age at death
65–74 294 (3.0) 254 (1.7)
75–84 4,075 (41.3) 5,028 (32.5)
85–94 5,215 (52.9) 9,232 (59.6)
95–104 277 (2.8) 958 (6.2)
≥105 1 (0.0) 11 (0.1)
Year of death
2005 1,204 (12.2) 1,772 (11.4)
2006 2,236 (22.7) 3,199 (20.7)
2007 2,351 (23.8) 3,473 (22.4)
2008 2,133 (21.6) 3,619 (23.4)
2009 1,938 (19.7) 3,420 (22.1)
Location of residence at death (remoteness area)
Major cities 6,147 (62.3) 9,530 (61.6)
Inner regional 2,777 (28.2) 4,400 (28.4)
Outer regional 872 (8.8) 1,410 (9.1)
Remote 39 (0.4) 81 (0.5)
Very remote 5 (0.1) 2 (0.0)
Missing 22 (0.2) 60 (0.4)
Socioeconomic disadvantage index at death
(Most disadvantaged) 1–2 1,160 (11.8) 1,862 (12.0)
3–4 2,831 (28.7) 4,470 (28.9)
5–6 2,032 (20.6) 3,085 (19.9)
7–8 1,418 (14.4) 2,248 (14.5)
(Least disadvantaged) 9–10 2,019 (20.5) 3,183 (20.6)
Missing 402 (4.1) 635 (4.1)
Charlson comorbidity burden1
0 3,105 (31.5) 4,451 (28.8)
1–2 1,500 (15.2) 2,068 (13.4)
≥3 1,713 (17.4) 1,578 (10.2)
No hospitalizations during
calculation period (cannot calculate)
3,544 (35.9) 7,386 (47.7)
RxRisk comorbidity burden2
0 461 (4.7) 846 (5.5)
1–2 1,298 (13.2) 2,130 (13.8)
3–5 3,865 (39.2) 6,104 (39.4)
≥6 4,238 (43.0) 6,403 (41.4)
1Calculated using hospitalizations in the 12-month period before the last 6
months of life (months 18 to 7 before death).
2Calculated using dispensing history in the 6-month period before the last 6
months of life (months 12 to 7 before death).
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We currently have the capacity to report cause of death
for decedents who died between 2005 and 2007 as the
ABS cause of death data are available in the NSW Registry
of Births, Deaths and Marriages in this period. We utilized
these data to determine the proportion of patients with a
cancer diagnosis whose cause of death was also cancer
and to understand the nature of other common medical
conditions at the end of life in our cohort.
 We identified cancer causes of death using the codes
C00-C43, C45–C97, D03, D05, D45, D46.0–D46.4,
D46.7, D46.9, D47.1 and D47.3. All of these cancers
are notifiable to the NSW CCR.
 We grouped non-cancer causes of death based on
categories used by the Australian Institute of Health
and Welfare (AIHW) and Charlson comorbidity index
[23-26]. The most common non-cancer causes of
death were heart failure (I21, I22, I25.2, I50, I70–I74,
I79.0, R02, Z95.8, Z95.9), cerebrovascular disease
(I60–I69), coronary heart disease (I20, I23, I24, I25.0,
I25.1, I25.3–I25.9), chronic obstructive pulmonary
disease (J40–J44) and dementia (F00–F03, F05.1,
G30, G31). Deaths that did not fall into these categories
were classified as “other”.
The NSW CCR also details cause of death in the
period 1994–2008 categorized according to cancer type
and non-cancer death, the latter not being specified be-
yond this category. As the ABS and NSW CCR registries
both measure cause of death, we analysed clients with
records in both registries (5,060) to determine the level
of agreement. Overall, there was a 97.7% agreement be-
tween the ABS and NSW CCR for the underlying cause
of death. The NSW CCR contains more specific informa-
tion on cancer deaths than the ABS as it uses ICD-O-3
codes and pathology information, as such we will use this
data source when examining differences in resource use
and cost by cancer cause of death.
Cohort characteristics
A total of 9,862 decedents met the eligibility criteria for
our cancer cohort and 15,483 for our non-cancer cohort
(Table 2). There were more males in the cancer cohort
(68.4%) compared with the non-cancer cohort (51.4%),
driven primarily by the high numbers of prostate cancer
diagnoses. The median age of the cancer cohort was 86
years (range 65–107) and 87 years (range 65–111) in the
non-cancer cohort; 52.9% of the cancer cohort and
59.6% of the non-cancer cohort died between 85 and 94
years of age. At the time of death, 61.9% of all decedents
resided in major cities and 11.9% resided in the most so-
cioeconomically disadvantaged neighbourhoods. Import-
antly, age at death, socioeconomic status and location of
Langton et al. Implementation Science  (2015) 10:25 Page 8 of 14residence were very similar across both cohorts. Comor-
bidity burden, as measured by the Charlson index [23]
was similar in both cohorts, however the percentage of
decedents with a comorbidity burden of 3 or more was
higher in the cancer cohort (17.4%) compared to the non-
cancer cohort (10.2%). As a Charlson score is calculated
using hospital admissions, it is likely to under-ascertain
comorbidity. In contrast, the RxRisk [27] comorbidity
score is based on prescriptions dispensed in the com-
munity, so more comorbidities are generally ascertained
by this measure; 95% of both cohorts have at least one
comorbidity based on RxRisk, and, the comorbidity
burden does not differ between the two cohorts.
Of the 9,862 decedents in our cancer cohort, the most
common cancer diagnoses were prostate (17.6%), colorec-
tal (10.6%) and lung cancer (9.6%). 16.8% of decedents
were diagnosed with more than one cancer (Table 3).
Median age at diagnosis was similar across cancer types
(80–85 years). However, there was substantial variation
in the median time from diagnosis until death, rangingTable 3 Cancer cohort characteristics by cancer type




All cancers 9,862 (100) 6,746 (68.4) 82.6 (54.5–105.6)
Prostate (C61) 1,735 (17.6) 1,735 (100) 80.8 (61.8–98.6)
Multiple cancers 1,652 (16.8) 1,322 (80.0) 83.5 (64.3–100.0)
Colorectal (C18–C21) 1,049 (10.6) 615 (58.6) 82.3 (56.8–101.7)
Lung (C33–C34) 951 (9.6) 630 (66.2) 82.6 (56.7–100.9)
Melanoma of skin (C43) 634 (6.4) 476 (78.1) 81.7 (57.8–99.3)
Haematological (C81–C96) 663 (6.7) 379 (57.2) 83.1 (60.8–102.4)
Other** 571 (5.80) 355 (62.2) 83.0 (60.8–100.3)
Breast (C50) 449 (4.6) 12 (2.7) 80.3 (54.5–105.6)
Digestive organs
(C15–C17, C22–C24)
471 (4.8) 281 (59.7) 83.3 (59.8–97.1)
Unknown primary site
(C26, C39, C76–C80)
389 (3.9) 209 (53.7) 85.5 (66.3–100.7)
Bladder (C67) 299 (3.0) 218 (72.9) 83.6 (64.0–98.3)
Pancreas (C25) 282 (2.9) 144 (51.1) 84.4 (67.9–97.9)
Head and neck
(C00–C14, C30–C32)
226 (2.3) 176 (77.9) 81.6 (56.8–99.9)
Female genital organs
(C51–C58)
183 (1.9) 0 (0) 82.3 (59.2–103.1)
Kidney (C64) 145 (1.5) 89 (61.4) 82.3 (63.3–94.9)
Connective and soft tissue
(C45, C47–C49)
99 (1.0) 74 (74.7) 81.7 (64.6–95.0)
Brain (C71) 64 (0.6) 31 (48.4) 82.3 (54.6–93.4)
*Includes clients with cancer cause of death identified in death registry data; these
degree of cancer spread information).
**Includes C37–C39, C40–C41, C46, C60, C62, C63, C65, C66, C68, C69, C70, C72, C73from 0.1 years in decedents with cancer of unknown
primary site to 5.3 years for prostate cancer. The major-
ity of cancers were in-situ or localized at the time of
diagnosis but this varied according to cancer type. The
degree of spread at diagnosis was unknown for many
cancers.
Information about cause of death is available for 13,575
decedents; 5,550 in the cancer cohort and 8,023 in the
non-cancer cohort, all of whom died during the period
2005–2007 (Table 4). In the cancer cohort, the most com-
mon cause of death was cancer (58.9%), followed by heart
failure (9.3%) and cerebrovascular disease (6%). In the co-
hort with no cancer diagnoses, the most common causes
of death were heart failure (20.0%), cerebrovascular disease
(15.4%) and coronary heart disease (12.8%).
Outcomes of interest and statistical analyses
We will examine resource use, associated costs and quality
of end-of-life care in the cancer and non-cancer cohorts.
Most of the studies undertaken in this research programTime from
diagnosis to
death






1.6 (0–15.8) 3,243 (32.9) 1,321 (13.4) 1,592 (16.1) 3,706 (37.6)
5.3 (0–15.8) 586 (34.2) 53 (3.1) 150 (8.6) 943 (54.3)
0.9 (0–14.7) 548 (34.2) 217 (13.1) 300 (18.2) 578 (35.0)
2.6 (0–15.7) 322 (31.7) 403 (38.4) 169 (16.1) 154 (14.7)
0.4 (0–14.5) 202 (23.5) 131 (13.8) 294 (30.9) 311 (32.7)
4.1 (0–15.8) 278 (42.7) 80 (12.6) 59 (9.3) 39 (6.2)
1.2 (0–14.8) 451 (72.2) 8 (1.2) 9 (1.4) 593 (89.4)
2.4 (0–15.1) 40 (6.4) 25 (4.4) 14 (2.4) 262 (45.9)
4.9 (0–15.2) 187 (41.6) 122 (27.2) 24 (5.4) 115 (25.6)
0.6 (0–15.7) 134 (31.6) 98 (20.8) 91 (19.3) 137 (29.1)
0.1 (0–13.1) 1 (0.3) 13 (3.3) 242 (62.2) 132 (33.9)
1.5 (0–15.6) 117 (40.9) 33 (11.4) 25 (8.4) 124 (41.5)
0.2 (0–7.8) 50 (20.4) 23 (8.2) 101 (35.8) 99 (35.1)
2.9 (0–14.6) 96 (43.4) 49 (21.7) 7 (3.1) 73 (32.3)
1.2 (0–15.4) 52 (30.3) 38 (20.8) 54 (29.5) 39 (21.3)
2.0 (0–13.6) 54 (40.6) 15 (10.3) 39 (26.9) 36 (24.8)
0.7 (0–13.7) 28 (29.5) 12 (12.1) 14 (14.1) 42 (42.4)
0.2 (0–10.6) 31 (51.7) 1 (1.6) 0 29 (45.3)
clients do not have a cancer diagnosis in the NSW cancer registry (and no
–C75, D03, D05, D45, D46.0–D46.4, D46.7–D46.9, D47.1 and D47.3.







n % n % n %
Cause of death
Cancer (C00-C43, C45–C97, D03, D05, D45, D46.0–D46.4, D46.7, D46.9, D47.1, D47.3) 3,156 58.9 0 0 3,156 23.3
Heart failure (I21, I22, I25.2, I50, I70–I74, I79.0, R02, Z95.8, Z95.9) 515 9.3 1,603 20 2,118 15.6
Cerebrovascular disease (I60–I69) 333 6 1,232 15.4 1,565 11.5
Coronary heart disease (I20, I23, I24, I25.0, I25.1, I25.3–I25.9) 335 6 1,025 12.8 1,360 10
Chronic obstructive pulmonary disease (J40–J44) 175 3.1 545 6.8 720 5.3
Dementia (F00–F03, F05.1, G30, G31) 139 2.5 696 8.7 835 6.2
Other* 897 16.2 2,922 36.4 3,819 28.1
*Other ICD-10-coded causes of death not listed in the table.
Table 5 Number of records and person years in the last 6








Cancer cohort (n = 9,862)










Health services (MBS) 4,758,023 1,193,625 50,756
Prescription drugs (R/PBS) 3,459,325 594,474 50,756




Langton et al. Implementation Science  (2015) 10:25 Page 9 of 14will focus on the last 6 months of life (the most common
period of observation identified in our systematic review
of end-of-life cancer care) [10]. For the purpose of our
analyses, the last 6 months of life is defined as a period of
180 days including the day of death, based on constructed
“months” that consist of 30 days each. However, we have
the opportunity to study shorter (e.g. last month of life) or
longer periods (last 12 months of life), also used previously
in the literature. Additionally, we have the capacity to
examine changes in outcomes as death approaches. In the
first instance, we will report outcomes from January 2005
to December 2009, the period for which we currently have
information about all health services, medicines dispensed
and hospital and emergency department visits (Table 1).
Based on a 6-month end-of-life period, information is
available for approximately 1 million health service re-
cords and 400,000 pharmaceutical claims in the cancer co-
hort. In addition, there are approximately 30,000 hospital
separations and 12,000 emergency department admissions.
As the non-cancer cohort is larger than the cancer cohort,
we have more claims across all datasets and more person
years of observation for this cohort (Table 5).
Below we describe the general approaches we will take
to reporting end-of life resource use, costs and quality of
end-of-life care. Our methods are informed by best practice
approaches in the field. We have applied the Strengthening
the Reporting of Observational studies in Epidemiology
(STROBE) checklist [28] to this protocol (see Additional
file 1) and will apply this checklist for all research gen-
erated from this program.
Resource utilization
We will use multiple metrics to examine the nature and
extent of resource use at the end of life. For the cancer
and non-cancer cohorts, we will report on resource use
overall and by service type; at a patient level (e.g. descrip-
tion of services received by the typical decedent) and for
each cohort. We will also stratify resource use by age, sex,cause of death, socioeconomic status and remoteness.
We will examine the proportion of total resource use
accounted for by each service (e.g. the proportion of total
services accounted for by medications, hospitalizations).
In the cancer cohort, we will also stratify resource use by
cancer type and degree of spread (a proxy for cancer
stage) at diagnosis. Each dataset will be used to highlight
particular aspects of resource use.
Medicines use We mapped pharmaceutical items to
Anatomical Therapeutic Chemical (ATC) codes. We also
developed a coding scheme to classify medicines accord-
ing to their expected use towards the end of life. This
scheme was developed based on expert input and pub-
lished literature [29,30]. Medicines were classified based
on whether prescriptions for each medicine are likely to
remain unchanged, increase, decrease or both increase
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categories are as follows:
 Symptom management (expect an increase towards
the end of life)- such as analgesics for pain
management, antiemetics or laxatives;
 Active treatment (use at the end of life may vary by
patient and physician preference for active or
palliative care)- drugs used for a limited time period
with a specific purpose and measurable response
such as cancer medicines, antifungal or antibiotic
medicines to treat infections;
 Essential (expect prescribing to remain unchanged
at the end of life)- ceasing the drug may potentially
have serious adverse consequences for patients’
health/quality of life (e.g. anti-epileptic medications
or diabetes medicines);
 Non-essential or preventative (expect a decrease
towards the end of life in a terminally ill patient)-
ceasing the drug would have limited impact on the
quality of life of a terminally ill or palliative care
patient (e.g. vitamins, statins).
Health care services Due to the heterogeneous nature
of the health service items, we have classified all MBS
services and additional DVA-subsidized health services
into the categories which will allow us to report in more
detail the nature of health service use. This approach
was taken as unlike other jurisdictions, Australian health
care service items do not contain ICD codes, and their
categorical structure does not lend itself to research on
health service utilization. Our categories are as follows:
 Diagnostic tests, imaging and pathology;
 Visits to medical practitioners including general
practitioners, specialists (e.g. psychiatry, emergency
physician, pain and palliative care);
 Allied health (e.g. psychology, occupational therapy),
nursing services and multi-disciplinary care plans
and case conferences;
 Therapeutic procedures (e.g. chemotherapy,
radiation oncology and nuclear medicine);
 Surgeries;
 Dental care;
 Items associated with the receipt of medical services
that are for administration or billing purposes only
and do not represent a health care service in isolation
(e.g. management of bulk billing items that accompany
physician attendances that are bulk-billed). These
items will not be included in our resource use counts
but will be included in our cost analysis.
Hospital admissions We will examine the number of
hospital separations and describe the nature and extentof hospital stays. An episode of care is defined as the
period of admitted patient care between an admission and
a separation, characterized by only one care type. This
means that one hospital stay may include more than one
episode of care (e.g. transition from acute care to a re-
habilitation unit). In these cases, we can link multiple
episodes at a patient level and report on the total length
of stay and length of stay associated with each episode
of care. Additionally, we will examine whether the hospital
episode followed an emergency department presentation
and the separation mode (e.g. death, discharge). Finally,
we will report on the nature of hospital services provided
(e.g. cancer-related, palliative care).
Emergency department visits We will report on the
number and outcome of visits including the number that
result in hospital admission, death or discharge. ED pre-
sentations resulting in a hospital admission will also be
identified from the APDC (source of referral = ED) given
that the EDDC dataset does not capture all emergency
departments in NSW. This will enable us to compare ED
presentations rates resulting in a hospital admission in
the APDC with those obtained directly from the EDDC
dataset.
Costs
We will allocate unit costs to each item of resource use.
We will report costs by service type at a patient level and
for each cohort. We will also examine the contribution of
each service type to total costs. Costs will be stratified by
age, sex, cause of death, socioeconomic status, remoteness
and, for the cancer cohort, cancer type and degree of
spread at diagnosis.
Unit costs will be expressed according to a common
financial year 2009/10. At the time of writing, the most
current NSW Costs of Care Standards Report [31] is based
on the financial year 2009/10, so unless otherwise stated,
costs for all other datasets will also be benchmarked to
that year.
Medicines costs We will derive costs for individual items
based on benefit paid and patient co-payment. The benefit
paid includes dispensing fees, preparation fees, mark-ups
and any other pharmacist fees. The benefit paid will then
be inflated to a common price year, on a monthly basis
(as PBS schedules are updated monthly), using inflation
rates summarized in Table 6 derived from the AIHW
published PBS pharmaceuticals index [32]. Where applic-
able, we will add the RPBS co-payment at the time of
dispensing [33] to the benefit paid.
Health services costs We will derive item costs for each
service from the benefit paid and inflate costs to a com-
mon price year using inflation rates summarized in Table 6.
Table 6 Derived inflation rates used in converting medicines costs and medical services costs to the June 2010 price
level
2004–05 2005–06 2006–07 2007–08 2008–09 2009–10
Medicines costs1 Annual inflation rate (%) 0.1519 0.2123 0.2220 0.4832 0.1603 0.0200
Monthly inflation rate (%) 0.0126 0.0177 0.0185 0.0402 0.0133 0.0017
Medical services costs (MBS)2 Annual inflation rate (%) 7.0593 4.7857 2.7389 2.3338 1.8166
Medical services costs (dental) Annual inflation rate (%) 5.6317 4.5525 4.5682 3.8390 4.1654
Medical services costs (other) Annual inflation rate (%) 3.5392 3.8714 1.1189 1.3020 5.6757
1Derived inflation rates are applied on a monthly basis to reflect the fact that PBS price schedules are updated monthly. For example, if one AUD was spent in
March 2005, then its inflated value in June 2010 can be calculated as 1 × (1 + 0.0126%)3 × (1 + 0.2123%) × (1 + 0.2220%) × (1 + 0.4832%) × (1 + 0.1603%) × (1 + 0.0200%)
which equals 1.0114.
2Derived inflation rates are applied on an annual basis per November to October, to reflect the fact that the DVA Medical Fee Schedule is updated every November. For
this reason, we adjusted the annual inflation rates for this sector so that they cover a year starting from November (the price index constructed by the
Australian Institute of Health and Welfare is based on a financial year that starts from July). Based on these rates, if one AUD was spent on dental service in
March 2005, then its inflated value in June 2010 can be calculated as 1 × (1 + 5.6317%) × (1 + 4.5525%) × (1 + 4.5682%) × (1 + 3.8390%) × (1 + 4.1654%) which
equals 1.2491.
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tion rates from the AIHW Medicare medical services fees
index, dental services price index and other health practi-
tioner price index, respectively [32]. We will not make ad-
justments for co-payments, as all services provided to our
cohort are bulk-billed.
Hospital costs We will derive hospital admission costs,
based on AR-DRG, length of stay and mode of separation,
applying the approach described in Figure 1 of the NSW
Costs of Care Standards Report 2009/10 [31]; using
separate approaches for sub- and non-acute care (SNAP)
patients, which include admissions like rehabilitation,
palliative and maintenance care.
For SNAP AR-DRGs, we will apply per diem weights
to the average SNAP cost ($11,582 in 2009/10) for each
day in our observation period only (as admission may
have occurred before the start of this period). SNAP trim
points and cost weights for outlier days vary by class;
however, a SNAP class is not supplied in our dataset.
Consequently, we will use the inlier SNAP cost weight
(0.0424) which is the same for all SNAP classes. This will
be applied for each SNAP admission day in our observa-
tion period. Hospital costs for outpatients are assumed
to be captured as MBS items.
For acute care admissions (non-SNAP AR-DRGs), the
relevant cost weight will be multiplied by the base aver-
age cost ($3,840 excluding ED and ICU or $4,092 exclud-
ing ED only) with per diem rates applied for length of stay
exceeding specified trim points up to 120 days for each
AR-DRG. After a hospital stay of more than 120 days, a
flat rate of $200 per day will be applied. Although the
Costs of Care Standards cap the total cost at 365 days,
to avoid underestimating costs of care, we will continue
to apply a rate of $200 per day for hospitalization over
365 days. Where hospital episodes commenced prior to
our observation period, we will only assign per diem
costs to observed outlier days (days above the trimpoint); observed inlier days (below the trim point) are
costed on a pro rata basis.
Emergency department costs We will derive emergency
department costs using the average cost of emergency pre-
sentations ($396/presentation in 2009/10). The NSW
Costs of Care Standards Report 2009/10 (pp 14–15) as-
signs ED cost weights by “urgency and disposition group”,
which is based on triage category, visit type and mode
of separation [31]. However, triage category and visit
type are not available in our dataset. Therefore, we will
weight ED cost according to typical triage breakdown
and visit type for each mode of separation from NSW
Hospital Statistics [34].
Total cost To calculate the total cost, we will adopt an
approach to reduce the likelihood of double counting
the cost of services when adding together health care
services, medicines, hospital admissions and emergency
department costs. We will assume any health services
costs incurred at the same time as hospitalization will be
captured by the AR-DRG cost, and therefore, we will
only include out-of-hospital health services in our total
cost calculation. We will count all RPBS items; however,
for private hospital patients, we will deduct the pharmacy
cost from the total AR-DRG cost when calculating total
costs.
Quality of end-of-life cancer care: applying validated indicators
to the Australian setting
There are a growing number of studies using validated
indicators to assess quality and appropriateness of cancer
care [35-38]; our recent systematic review identified 15
studies using “quality” end-of-life care indicators. These
indicators were developed on the premise that quality
end-of-life care involves withdrawal or reductions in life-
extending (or “aggressive”) treatments and increased use
of palliative services and hospice care. The first study
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trative health data [36] covered multiple services such
as administration of chemotherapy, emergency depart-
ment visits, time spent in hospital and time spent in the
ICU at the end of life. Some specific examples include the
proportion of patients with at least one emergency depart-
ment visit or hospital admission in the last month of life.
These indicators have been influential, with many subse-
quent studies adopting similar indicators.
Across the 15 studies identified in our systematic review,
there was some variability in the definitions of quality of
care used; however, the aspects of resource use were simi-
lar, and most studies focused on services used in the last
month or last 2 weeks of life. Commonly used “aggressive”
indicators include intensive care or emergency department
visits, inpatient hospital admissions, chemotherapy and
life-sustaining treatments close to death. Palliative indi-
cators focus on hospice care, pain relief (opioids) and
primary and community care at the end of life.
To date, none of the indicators have been applied in
the Australian setting. We will use best practice methods
to adapt and refine these validated indicators of end-
of-life cancer care using the datasets outlined in this
protocol. To ensure our indicators are applicable to the
Australian setting, we will consult with palliative experts
(including clinicians and patients) and use our data on re-
source use in the last 6 months of life in our cancer cohort
to empirically derive Australian-specific thresholds.
Factors associated with outcomes of interest
Regression methods to determine factors related to re-
source utilization and costs will be based on the specific
question and the distribution of the data. For example,
when modelling counts of services, we may use a Poisson
or negative binomial analysis depending on whether the
data are over-dispersed. Factors related to binary out-
comes, such as quality of end-of-life care, will be deter-
mined using logistic regression. The literature suggests
that a range of factors impact on the nature and extent of
resource use at the end of life; we have the capacity to
examine the impact of age [39-47], sex [39-47], comorbidity
burden [40,48,49] and location of residence (geographical
and residence in an aged care facility versus community
dwelling decedents) [12,41] on outcomes of interest. We
will also examine trends by year of death. Additionally, we
will examine the impact of a number of clinical factors
including cause of death (cancer versus non-cancer;
where available) and, in the cancer cohort, cancer type,
spread at diagnosis and time from diagnosis to death.
Dissemination plan
End-of-life care is a research priority in Australia and
internationally. Research from this program will be sub-
mitted to international peer-reviewed journals, and resultswill be presented at national and international confer-
ences. Particular journals and conferences will be focused
on oncology, health services research, health economics
and the implementation of health services research into
clinical care and policy. We will consult clinicians, policy
makers and consumers where appropriate for guidance in
interpreting results and communicating results to target
audiences; this may involve producing lay summaries of
research findings. In accordance with our DVA data agree-
ment, we will submit all data that will be communicated
in the public domain to the DVA for review and approval.
Direct access to the data and analytical files is not permit-
ted without the expressed permission of the approving
human research ethics committees and data custodians.
Discussion
End-of-life care is a high-priority research area for health
policy and planning. The topic has recently been the sub-
ject of editorials and research articles in the highest rank-
ing general medicine and cancer journals internationally
[2,3]. It has also been identified as a research priority by
the leading Australian cancer advocacy group [50]. The
research outlined in this protocol makes the best use of
comprehensive linked datasets and addresses a key evi-
dence gap in the Australian setting and internationally.
The large body of research on end-of-life patterns of
care in the North American setting highlights the import-
ance of the local environment and that the delivery of
palliative care is highly jurisdiction specific [51]. The five
papers reporting the results of research into end-of-life
care in the Australian setting to date [7-9,11,12] have
focused primarily on hospital services; our program will
build on this work to provide a more comprehensive
picture of end-of-life care. Additionally, this program is
the first to apply quality of care markers of end-of-life
care outside the North American setting.
The strengths of this program lie in the use of best prac-
tice methods to examine comprehensive data holdings in-
cluding medicines, hospital services and other health care
services. The limitations of using administrative data for
research purposes are well recognized; however, as dem-
onstrated in our recent systematic review, the volume of
research using these data to examine the quality of end-
of-life care continues to grow [10] and with this comes
improved methodology such as validated indicators and
risk-adjustment methods. While the DVA population rep-
resents a substantial proportion of the elderly population
in Australia, the generalizability of our findings beyond
DVA clients is a potential limitation of this program. Im-
portantly, data linkage initiatives currently underway will
improve data access and allow researchers to conduct ob-
servational research on end-of-life resource use and costs
in the general adult population, building on the founda-
tions of this program.
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